Institute of Cellular Therapeutics
Stem Cell and Organ Transplantation, Cellular Therapeutics, GMP facility, Manufacturing
Cell-based therapies are increasingly used individualized to treat patients with blood disorders, cancers, and serious traumatic or degenerative tissue and organ damage in order to increase survival. In the Institute of Cellular Therapeutics new cell-based therapies (Advanced Therapy Medicinal Products (ATMPs)) are developed and manufactured in three clean rooms observing good manufacturing practice (GMP) conditioning. Beside the manufacturing license for various preparations of stem cell products and antigen-specific T cells, the further focus are regulatory T cells, natural killer cells, mesenchymal stem cells and gen-manipulated effector cells. As a core facility of the Integrated Research and Treatment Centre for Transplantation (IFB-Tx), development is done in a close cooperation to the different scientific groups of the MHH.